In addition, GWAS have discovered genetic variations in the CR1 and BIN1 genes that are associated with an increased risk of AD and may also affect how individuals respond to anti-amyloid medications (Lambert et al., 2013; Hardy, 2009; Selkoe and Hardy, 2016). The gene discussed is BIN1; the disease is Alzheimer disease.